CyPath Lung Q2 results
CyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.
View filing at SEC.gov →9 most recent filings and news items mentioning BIAF. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BIAF/news?limit=20"
Pull BIAF filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayCyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.
View filing at SEC.gov →bioAffinity Technologies released a clinical review outlining protocols for using CyPath Lung in pulmonary nodule evaluation, addressing the need for risk stratification in primary care, pulmonology, and oncology settings.
View filing at SEC.gov →bioAffinity Technologies has partnered with Pictor to develop and commercialize diagnostic tests for asthma and COPD, creating a more comprehensive picture of lung inflammation. This collaboration increases laboratory throughput.
View filing at SEC.gov →bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth of over 200% to a new record driven by increased physician adoption and repeat utilization. The acceleration in test volume underscores a strong commercial trajectory for the company's non-invasive lung cancer dia
View filing at SEC.gov →Unit sales for CyPath Lung increased nearly 300% in April 2026 versus the prior year. The company also announced a collaboration with Philips to enhance lung cancer screening for U.S. veterans.
View filing at SEC.gov →bioAffinity Technologies entered into a placement agency agreement with WallachBeth Capital to sell up to $3.2 million in securities comprising common stock at $0.80 per share and pre-funded warrants at $0.793. The offering provides capital for the company through a registered di
View filing at SEC.gov →bioAffinity Technologies partnered with Philips and 4DMedical to host a July 21, 2026 webinar on lung health screening for U.S. veterans, featuring CyPath Lung testing and mobile CT imaging. The initiative aims to improve early detection and access to lung cancer diagnostics for
View filing at SEC.gov →bioAffinity Technologies announced a June 16 webinar featuring physicians discussing real-world benefits of its noninvasive CyPath Lung test for early-stage lung cancer detection. The event highlights the test's clinical utility in reducing unnecessary invasive procedures and sup
View filing at SEC.gov →bioAffinity Technologies announced notification of patent allowance from Mexico's Institute of Industrial Property for methods using flow cytometry and antibodies to detect lung cancer. The patent strengthens the company's global IP portfolio for its CyPath Lung diagnostic platfo
View filing at SEC.gov →